SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Pharmos (PARS)
PARS 2.700+13.6%Jan 21 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Dr. John M. de Castro who wrote ()10/29/1998 8:26:00 AM
From: yosi s  Read Replies (1) of 1386
 
Great to see PARS in biotech.
As Pharmos is one of few biotech with revenues, and within 2 Q being in positive cash flow.
About to enter phase 3 for HU 211 Dexanabinol. treatment for head trauma. potential treatment for stroke, MS.
Inflamatory bowl disease, Dexanabinol mechanism of action being oxygen radical scavanger. and anti Alpha tumor necrosis factor.
Huge potential for growth.
Over 300 000 severe head trauma in USA alone.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News